CNR1 and fatty liver disease: An example of these compounds is MRI-1569, a hybrid CB1 inverse agonist/inducible nitric oxide synthetase (iNOS) inhibitor that reduced food intake and body weight and improved glucose tolerance and hepatic steatosis [191].